Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

459
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
459
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

639
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
639
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

498
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
498
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

520
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
520
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries.

International journal of cardiology·2026
Same author

iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease.

American journal of preventive cardiology·2026
Same author

Echo-Based, Artificial Intelligence Algorithm Identifies Future Heart Failure Cases: A Blinded, Retrospective Clinical Trial Report.

JACC. Heart failure·2026
Same author

Delirium: an urgent health priority in Australian hospitals.

Public health research & practice·2026
Same author

Exploring Technological Solutions for Interoperability Between Patient Electronic Medical Records and Clinical Registries: Scoping Review.

Journal of medical Internet research·2026
Same author

Association of postoperative elevation of biomarkers of neural injury in blood with postoperative neurocognitive disorders in adults receiving general anaesthesia: a systematic review.

British journal of anaesthesia·2026

Related Experiment Video

Updated: Mar 14, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.1K

Improving medication titration in heart failure by embedding a structured medication titration plan.

Annabel Hickey1, Jessica Suna2, Louise Marquart3

  • 1Advanced Heart Failure and Cardiac Transplant Unit, The Prince Charles Hospital, Brisbane, Australia.

International Journal of Cardiology
|September 20, 2016
PubMed
Summary

Implementing a structured medication titration plan improved heart failure medication management. This enhanced communication between hospital and primary care, leading to more patients reaching target drug doses within six months.

Keywords:
ACE inhibitorBeta-blockerHFrEFHeart failureMedicationTitration

More Related Videos

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K

Related Experiment Videos

Last Updated: Mar 14, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.1K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K

Area of Science:

  • Cardiology
  • Pharmacology
  • Health Services Research

Background:

  • Heart failure (HF) management requires effective medication up-titration to target doses.
  • Transitional care from hospital to primary care presents challenges in optimizing HF pharmacotherapy.
  • Improving communication is crucial for successful medication titration in heart failure patients.

Purpose of the Study:

  • To enhance medication titration to target doses for heart failure patients.
  • To improve communication between hospital and primary care settings for HF medication management.
  • To evaluate the impact of a structured medication titration plan on achieving evidence-based therapy goals.

Main Methods:

  • A quality improvement project involving three heart failure disease management (HFDM) services in Australia.
  • Collaborative design and iterative implementation of a structured medication titration plan.
  • Utilized methods: awareness raising, education, audit and feedback, work practice integration, and incentives.
  • Evaluation through sequential audits assessing process and outcome measures (proportion of patients achieving target dose).

Main Results:

  • Increased utilization of the medication titration plan across HFDM services.
  • Observed a shift towards greater primary care responsibility for medication titration.
  • Significant increase in patients achieving target doses of ACEI/ARB (37% to 55%) and beta-blockers (38% to 51%).
  • Patients receiving a titration plan were more likely to reach target doses of ACEI/ARB and beta-blockers within six months post-discharge.

Conclusions:

  • A structured medication titration plan was successfully implemented in HFDM services.
  • The plan improved transitional communication between hospital and primary care.
  • Achievement of target doses for evidence-based HF therapies was enhanced within six months post-discharge.